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Multiple myeloma (MM) is a hematological malignancy resulting from the uncontrolled proliferation of antibody-
producing plasma cells in the bone marrow. At diagnosis, independent plasma cell tumors are found throughout
the skeleton. The recirculation of mutant plasma cells from the initial lesion and their recolonization of distant
marrow sites are thought to occur by a process similar to solid tumor metastasis. However, the efficiency of this
bone marrow homing process and the proportion of disseminated cells that actively divide and contribute to new
tumor growth in MM are both unknown. We used the C57BL/KaLwRij mouse model of myeloma, lentiviral-
mediated DNA barcoding of 5TGM1 myeloma cells, and next-generation sequencing to investigate the relative
efficiency of plasma cell migration to, and growth within, the bone marrow. This approach revealed three major
findings: firstly, establishment of metastasis within the bone marrow was extremely inefficient, with
approximately 0.01% of circulating myeloma cells becoming resident long term in the bone marrow of each
long bone; secondly, the individual cells of each metastasis exhibited marked differences in their proliferative
fates, with the majority of final tumor burden within a bone being attributable to the progeny of between 1 and 8
cells; and, thirdly, the proliferative fate of individual clonal plasma cells differed at each bone marrow site in which
the cells “landed.” These findings suggest that individual myeloma plasma cells are subjected to vastly different
selection pressures within the bone marrow microenvironment, highlighting the importance of niche-driven
factors, which determine the disease course and outcome.
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Multiple myeloma (MM) is a hematological malignancy caused by
the clonal proliferation of antibody-producing plasma cells (PCs)
within the bone marrow [1]. MM is the second most common
hematological malignancy with an incidence of 6.6 per 100,000 in
the United States [2]. Despite recent therapeutic advances, MM
remains a largely incurable cancer, relapse is common, and the 5-year
relative survival rate is approximately 50% [2]. Symptomatic MM is
characterized by N10% clonal PCs within the bone marrow and the
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renal insufficiency, anemia, or bone lesions) or other
myeloma-defining events [3]. The disease is characterized by multiple
sites of tumor growth throughout the axial and appendicular skeleton.
It is usually preceded by the asymptomatic condition, termed
monoclonal gammopathy of undetermined significance (MGUS),
which is characterized by a lower tumor burden and the absence of
end organ damage [3,4]. Despite having multiple sites of tumor
growth within the bone marrow, patients with MGUS transition to
MM at a rate of 1% per annum. What triggers this transition remains
to be determined, but studies suggest that it is a combination of
intrinsic changes, such as an increase in the mutational load of the
clonal PCs [5], and extrinsic cellular changes within the bone marrow
microenvironment [6] involving stromal cells [7], macrophages [8],
and osteoclasts [9,10]. The development of both MGUS and MM
relies on the systemic recirculation and continued bone marrow
metastasis of myeloma PCs from the site of the initial lesion to distal
sites [11]. As the mechanisms of myeloma PC metastasis remain to be
fully elucidated, a more complete understanding of these processes
would assist with the design of strategies to prevent posttherapy
disease relapse and prevent the reestablishment of mutant PCs at new
bone sites.
To date, the in vivomodels used to investigate the migration of and
dissemination of myeloma PCs have relied on the MM1.S xenogeneic
transplant model [12] or the 5TMM series of transplantable C57BL/
KaLwRij-derived tumors [13]. Using in vivo microscopy, small
numbers of fluorescently labeled MM1.S cells have been shown to
rapidly migrate from the peripheral circulation to the bone marrow
[14–16]. However, there remains little understanding of the number
of MM1.S cells, of the initial migrating pool, that enter the bone
marrow and become long-term resident MM cells. Furthermore,
these studies were limited to the examination of the bones of the
calvaria, which, while more accessible, have a different ontogeny and
physiology to the long bones of the appendicular skeleton.
Interestingly, studies using radioactively labeled 5T2MM or
5T33MM cells in C57BL/KaLwRij mice suggest that approximately
10% to 15% of intravenously injected cells home to the skeleton
within 18 hours [17]. We have recently used a membrane-label
retention system and longitudinal intravital microscopy to assess the
fates of 5TGM1 and 5T2MM PCs following intravenous injection in
C57BL/KaLwRij mice. These studies highlight that the 5TGM1 and
5T2MM PCs that migrate to the bone marrow following intravenous
injection have different fates, with the majority remaining dormant,
while only a small number proliferate rapidly [9]. Again, enumeration
of the absolute numbers of these colonizing cells was not possible, and
the nature of any ancestral relationships between the dormant cells
and the proliferative cells could not be measured.
Cellular DNA “barcoding” and deep sequencing [18] have been
previously combined to examine lineage differentiation of hemato-
poietic stem cells/progenitors [19,20]and mammary epithelial cells
[21] in vivo, and to track the clonal origins of hepatocyte and Bcr-Abl
leukemia cell engraftment [22,23] and Cbx7-induced leukemias [24].
In the present study, we used functionally neutral, heritable DNA
tags to uniquely label each myeloma PC. As each daughter cell will
harbor the same DNA barcode as their parental cell, this enables the
tracking of the progeny of individual injected MM PC. Furthermore,
it makes it possible to measure the precise number of 5TGM1 cells
that migrate and become resident long term in the bone marrow of
the long bones of C57BL/KaLwRij mice. We propose that the relativefrequency of each barcode in an established MM tumor could provide
a direct measure of the number of proliferative versus dormant
myeloma PC clones within the bone marrow. Using this approach,
we show, for the first time, that large numbers of distinct, unrelated
MM PCs become stably resident in the bone marrow but that the
progeny of only a small number of these myeloma PCs contribute to




Oligo duplexes encoding a partially degenerate DNA “barcode”




In vitro phosphorylated duplex barcodes were subsequently cloned
into the pLeGO-T2 lentiviral vector [25] (gift from Boris Fehse,
Addgene plasmid # 27342) using ApaI and NotI, replacing one of the
LoxP sites in the original vector. The ligated barcode-lentiviral library
was transformed into MegaX DH10B T1R electrocompetent cells
(Invitrogen) by electroporation at 2.0 kV, 200 Ω, and 25 μF with a
Gene Pulser (Bio-Rad). An aliquot of the transformed Escherichia coli
was plated onto agar overnight and gave an estimated CFU frequency
of ~3 × 106 for the whole library. Concurrently, a DNA preparation
of the whole barcode-lentiviral library was generated from 400 ml of
overnight culture using the Pure Link HiPure Maxiprep kit
(Invitrogen). Screening by ApaI and XmaI double digestion of
plasmid DNA isolated from 48 colonies showed an oligo duplex
insertion frequency of 100% (with only 4 colonies showing bands
indicative of tandem oligo duplex insertion). The following two
primers were used in 30 cycles of polymerase chain reactions (PCRs)
to amplify the “degenerate barcode” from genomic DNA isolated
from whole bone marrow using PfuTurbo polymerase (Agilent
Technologies):CS1.LeGO.T2.F-5′ ACA CTG ACG ACA TGG TTC TACA
ACA GGG ACA GCA GAG ATC CAG 3′
CS2.LeGO.T2.R-5′ TAC GGT AGC AGA GAC TTG GTCT
CGT TAC TGC AGC TAG CTT GCC 3′
PCR products were then purified following agarose gel electro-
phoresis using an Ultraclean Gelspin DNA extraction kit (Mo Bio
Laboratories). Ten nanograms of purified PCR product was amplified
for a further 10 cycles using High Fidelity Master Mix (Roche) and
384 Barcode Access Array primers (Fluidigm). Final amplicons were
purified with Ampure XP beads (Beckman Coulter) and quantitated
with Qubit. Libraries were spiked with PhiX prior to running on the
MiSeq (Illumina). A v2 500-cycle kit was used to perform 2 × 180-bp
reads plus 10-bp index reads.
Sequencing Metrics and Bioinformatics Analysis
Sequencing was performed on the Illumina MiSeq and NextSeq
instruments using barcodes with a minimumHamming distance of 3.
Base calling was performed by Illumina RTA version 1.18.54 for the
MiSeq and CASAVA 1.8.2 for the NextSeq with default parameters.
The FastQ files were trimmed using Cutadapt v1.3 [26] using the
front adapter ACAGGGACAGCAGAGATCCAGTTTGGTTAGT
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ACCTGTAGGTTTGGCAAGCTAGCTGCAGTAACG for the
first of pair reads (R1) and swapped and reverse complimented for
the second of pair reads (R2). A 10% error rate was allowed, and only
reads trimmed for both adapters were kept for further analysis.
Trimmed reads were matched against the barcode pattern
ATNNTAANNATCNNGATSSAAANNGGTNNAACNNTGT
where N can be any base and S is G or C, and then unique sequences
conforming to the pattern were counted. Barcodes from the initial
barcode library pools were kept and used to filter remaining
experiments. Source code is hosted online at https://bitbucket.org/
sacgf/17hewetttumorbarcodes. Library complexity (number of
unique barcodes) was estimated from PCR amplification and deep
sequencing of the maxiprep. Four independent PCRs were performed
on the library and sequenced. A “catalogue” of verified barcodes was
generated from barcode sequences that were detected in two out of
the four replicate PCRs. The size of this catalogue of verified barcodes
was slightly higher than that obtained from CFU estimation (4.2 ×
106).
Cell Lines
Mouse 5TGM1 myeloma cells [27] were maintained in Iscove's
modified Dulbecco's medium (SIGMA) supplemented with 20%
fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin, 100
μg/ml streptomycin, 1 mM sodium pyruvate, and 10 mM
hydroxyethyl piperazineethanesulfonic acid (Life Technologies). We
have previously modified the 5TGM1 cells [28] with a trimodality
retroviral NES-TGL construct [29,30] encoding thymidine kinase,
green fluorescent protein (GFP), and firefly luciferase [27], and a new
clonal subline was established that exhibits consistent bone tropism
[27,31].
In Vivo Myeloma Model
Viral particles containing pLeGO-T2 barcode library were
generated following Lipofectamine 2000 (Invitrogen) transfection
of HEK293T cells concomitantly with psPAX2 (gift from Didier
Trono, Addgene plasmid #12260) and pECO (Clontech) packaging
constructs. 5TGM1 cells were infected with lentiviral particles by
centrifugation at 1000g for 1 hour with 8 μg/ml polybrene. Forty
hours later, tandem dimer tomato (tdT)–positive 5TGM1 cells that
had been successfully transduced with the lentiviral-barcode library
were isolated by flow cytometry. Single infected cells were also
isolated by flow cytometry. Clonal cell lines established from these
single cells were screened for barcode-lentivirus insertion frequencies
following PCR and Sanger sequencing. After brief recovery at 37°C,
the barcoded cells were injected via the tail vein into 6- to 8-week-old
C57BL/KaLwRij mice as previously described [27]. Briefly, 5TGM1
cells were resuspended at 5 × 106 cells per ml in phosphate-buffered
saline (PBS), and then 5 × 105 cells were injected into the tail vein of
6- to 8-week-old C57BL/KaLwRij mice. Growth of tumors was
monitored by whole animal bioluminescent imaging (BLI) using a
Xenogen IVIS 100 Imaging System (Caliper Life Sciences) after
intraperitoneal injection of 150 mg/kg of D-Luciferin (BIOSYNTH).
Tumor burden was quantitated using Living Image software. Long
bones with the highest tumor burden were dissected, and the bone
marrow was harvested into PBS, 2% FCS, and 2 mM EDTA (PFE).
Genomic DNA was extracted from bone marrow cells using DNeasy
Blood and Tissue Kit (QIAGEN) according to manufacturer's
instructions.Results
DNA Barcoding of 5TGM1 Cells In Vitro and In Vivo
The 5TGM1-C57BL/KaLwRij mouse model of myeloma faith-
fully replicates many of the features of aggressive myeloma
[27,31–33]. In this model, 5 × 105 5TGM1 cells are routinely
injected via the tail vein, after which an unknown number of these
cells home to and then proliferate at multiple sites within the apical
and appendicular skeleton, leading to very high levels of tumor
burden within 4 weeks [27,31]. In this study, each 5TGM1 PC was
uniquely marked with a permanent viral-integrated DNA barcode,
allowing assessment of the fate of each clone and its progeny. The read
counts generated for each tag/barcode, following deep sequencing,
allowed for the direct quantitation of the contribution of the progeny
of each individually tagged cell with respect to final tumor burden
within each long bone (see Figure 1 for experimental plan). To
achieve this, a partially degenerate oligonucleotide duplex was cloned
into a lentiviral vector containing a tdT fluorescence reporter. The
degenerate oligonucleotide was a longer version of a previously used
barcode sequence [19,21] and is predicted to yield 6.7 × 107 potential
unique nucleotide combinations. Estimation of the complexity of the
resulting barcode-lentiviral library by enumeration of the colony
forming units and by deep sequencing revealed that the constructed
library had between 3 × 106 and 4 × 106 barcodes. 5TGM1 cells were
infected with this library, and transduced cells were isolated based on
their GFP+tdT+ phenotype. In order to limit the number of 5TGM1
cells harboring more than one DNA barcode [18], the viral
particles were titered to maintain a 5TGM1 transduction efficiency
of only 10%. Analysis of 5TGM1 subclones derived from
single cells post lentiviral infection showed that more than 70%
of the GFP+tdT+5TGM1 cells contained a single DNA barcode
(data not shown).
In order to assess whether there were intrinsic differences in the
proliferation rates of individual 5TGM1 cells within our clonally
derived cell line, the barcoded 5TGM1 cells (5 × 105 cells) were
initially used to seed a culture that was maintained in vitro for 28
days. As anticipated, the day 0 and day 28 in vitro samples contained
large numbers of different barcodes (75,812 and 21,504, respectively)
with no high-frequency “common” barcodes present at N5% of the
total reads (Figure 2, Supplementary Table S1). Indeed, only 4
barcodes out of a combined 97,316 in vitro barcode sequences
individually constituted N0.1% of the total reads, consistent with all
the barcoded cells proliferating at very similar rates. Given the
random nature of the lentiviral integration, occasional insertion-
mediated inactivation of a tumor suppressor gene or activation of a
proto-oncogene, which would provide an intrinsic growth advan-
tages to some of the barcoded cells, cannot be actively avoided.
However, based on the data presented here, we saw no evidence of
such events, as no highly proliferative barcoded cells were present in
the in vitro culture.
DNA Barcode Quantitation
To investigate whether the mapped read counts provide an
accurate measure of the relative frequencies of low-frequency clones,
we also performed deep sequencing on admixtures of two 5TGM1
subclones each harboring a single barcode. Clone #23 and clone #31
were mixed in the following three ratios: 99 to 1, 99.9 to 0.1, and
99.99 to 0.01. Each sample had 190,000 to 210,000 mapped reads.
The observed ratios from barcode read depth were 98.30 to 1.02,
Figure 1. DNA-barcoding experimental workflow. The strategy for tracking uniquely labeled 5TGM1 cells in vitro and in vivo using a
DNA-barcode lentiviral library is shown.
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remarkable alignment to expected ratios highlights that barcode-read
counting of rare cells is quantitative. It also indicates the sensitivity of
the approach, with 1 in 1000 cells being readily detectable.
In order to investigate the potential cross-contamination between
samples and the degree of nonspecific background noise in the
barcoding system as a whole, these single-barcode controls detailed
above were sequenced alongside the experimental tumor samples
detailed later (Supplementary Table S2). As expected, the vast
majority of the sequences in the two control samples were the
predicted barcode (99.37% for clone #23, 99.61% for clone #31).
However, each sample did show a large number of additional
low-frequency barcodes (n = 121 barcodes in clone #23; n = 132 in
clone #31). Careful examination of the sequence of each of these
additional barcodes revealed that a proportion of these barcodes were
likely to be the result of sequencing errors rather than contamination.
As such, 22.7% to 46.3% of these barcodes were only 1 or 2
mismatches away from the expected sequence (n = 56 barcodes in
clone #23, and n = 30 barcodes for clone #31). Scoring the single and
double mismatches reveals an error rate of 0.006 per base for
clone#23 and 0.002 per base for clone#31. These findings are in line
with previous estimates of Miseq error rates ranging from 0.001 to
0.01 per base [34–36]. For clone #23, 13/15 of the next mostfrequent barcode sequences (after the correct sequence) all differed by
1 to 2 mismatches. For clone #31, 6/9 of the next most frequent
barcode sequences (after the correct sequence) all differed by 1 to 2
mismatches (Supplementary Table S2). The second type of low--
frequency barcodes was unrelated to the cloned barcode and is likely
intersample contaminants. Many of these were subsequently seen to
be common barcodes from other tumor samples or single clones. The
three most frequent contaminants of this type, seen in clone #23,
were present at read counts of 25, 12, and 9 (in a total read count of
193,101) representing 0.013%, 0.006%, and 0.005% of the totals,
respectively. These findings suggest that even if mismatch errors are
excluded, it is challenging to confidently call the exact numbers of
low-frequency clones (i.e., those contributing to b0.02% of the total
reads for each sample).
5TGM1 Growth Kinetics In Vivo
In order to investigate the growth of 5TGM1 tumors in vivo, two
independent experiments were carried out in which 5 × 105 cells were
injected into each of the 5 C57BL/KaLwRij mice, and tumors were
allowed to establish for 28 days (Figure 1). As the cells were previously
infected with a lentiviral construct harboring a luciferase reporter
[29,32], tumor growth could be monitored by whole animal BLI at
weekly intervals. At day 28, bone marrow was collected from
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Figure 2. Growth heterogeneity of myeloma cells in vivo compared to in vitro as revealed by DNA barcoding. (A) Barcode read count
metrics are shown for PCR products generated from in vitro (day 0, day 28) 5TGM1 cultures versus in vivo 5TGM1 skeletal tumors (day
28). The numbers of barcodes falling into the “rare” (b0.1% of total reads for tumor) and “common” (N5% of total read for tumor)
frequency subclasses of barcodes are indicated. (B) Summaries of the percentages of each tumor mass (i.e., total number of read counts)
that was attributable to each frequency subclass of barcode. The numbers of individual barcodes that were of the common subclass in
each tumor are also shown. (C) Graphical representation of the growth heterogeneity that is seen in vivo compared to in vitro. The
proportion of each sample that is attributable to barcodes of each frequency subclass is shown by the different colors. For the in vivo
tumor samples, the absolute numbers of common (N5%) barcodes and the total numbers of individual barcodes detected are
superimposed over and above the histogram bars respectively. Key: R/L = left/right; F/T = femur/tibia.
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BLI. Deep sequencing and deconvolution of barcode frequencies
were carried out, and the barcodes were then grouped according to
their relative abundance within each long bone and separated into
three classes: 1) “common” barcodes constituting N5% of the total
tumor mass (i.e., total number of mapped reads), 2) barcodes
constituting 0.1% to 5% of the total tumor mass, and 3) “rare”
barcodes constituting b0.1% of the total tumor mass.
In the initial proof-of-concept experiment, a total of 14 different
long bones were isolated from 5 tumor-bearing mice, and barcode
frequency was assessed (Figure 2, Supplementary Table S1). In
contrast to the in vitro findings, the in vivo samples exhibited a
remarkable skewing, with the bulk of the reads within each tumor
derived from a very small number of barcodes. Thus, there was a
median of just 6 “common” (N5%) barcodes per tumor (range: 3-8;
n = 14 tumors) which made up an average of 68.6% of each tumor
(range: 52.5%-84.0%). Each of the 78 common barcodes seen across
the tumor set was unique (Supplementary Table S3). In contrast, a
large number of “rare” (b0.1%) barcodes were evident in each tumor
sample, but their combined contribution to the overall tumor mass
was very small. Thus, the tumors recovered from all mice had a
median of 73 “rare” barcodes each (range: 41-103), with these
rare barcodes making up an average of 4.4% of each total tumor
(range: 2.4%-9.9%). Together, these results suggest that only a smallnumber of injected 5TGM1 PCs home to, and persist within, the
bone marrow and that very few of the clones actively proliferate to
generate the majority of the tumor burden.
To more accurately evaluate the consistent clonal dominance
observed in vivo, a second experiment was performed with much
higher sequencing depth. In an effort to eliminate any false-positive
barcodes, particularly infrequent barcode sequences that may have
been introduced by PCR or Illumina sequencing errors, the following
precautions were observed, in keeping with the recommendations of
Naik et al. [18]: 1) each tumor DNA sample was independently
amplified in separate PCRs, and only those barcodes that were
detectable by next-generation sequencing (NGS) from both PCRs
were retained; 2) only barcodes that were present in both the tumor
DNA sample and the reference catalogue of barcodes from the
original lentiviral barcode library were included (with the exception of
the common subclass of barcodes); 3) barcodes which differed by only
1 to 2 mismatches from barcodes with N10,000 reads within each
tumor were discounted as PCR/Miseq errors; and 4) to increase the
accuracy of the barcode enumeration, only samples with a final
mapped read depth of at least 10,000 reads were analyzed, leaving
assessable data from 15 tumors which were recovered from 5 different
mice. As described above, the barcodes were partitioned according to
their frequency into three subclasses (Figure 3, Supplementary Table S4).
As with the first in vivo experiment, a large number of rare barcodes
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Figure 3. DNA barcoding shows the growth heterogeneity of myeloma cells in a second in vivo experiment. (A) Barcode read count
metrics are shown for PCR products generated from in vivo 5TGM1 skeletal tumors (day 28). The numbers of barcodes falling into the rare
(b0.1%) and common (N5%) frequency subclasses of barcodes are indicated. (B) Summaries of the percentages of each tumor mass that
was attributable to each frequency subclass of barcode. The numbers of individual barcodes that were of the common subclass in each
tumor are also shown. (C) Graphical representation of the growth heterogeneity that is seen in vivo. The proportion of each sample that is
attributable to barcodes of each frequency subclass is shown by the different colors. The absolute numbers of common (N5%) barcodes
and the total numbers of individual barcodes detected are superimposed over and above the histogram bars respectively. Key: R/L = left/
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Figure 4. Evidence of sharedbarcodesbetweendifferent bones. The
relative frequencies (as percentage of total reads) and identities
(colors) of barcodes enumerated in 5 different long bones from
mouse 1.2 are shown. Key: R/L = left/right; F/T = femur/tibia.
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of the tumor mass resulted from the expansion of a very small number of
“common” barcodes (median: 2, range: 1-6). The number of “common”
barcodes per long bone ranged from single barcodes, which constituted
98% of the tumor mass of both the right humerus of mouse 2.1 and the
left femur of mouse 2.NM, to 6 barcodes, which made up 92% of the
tumor mass in left tibia of mouse 1.2.The common barcodes identified
across all tumors and all mice are shown in Supplementary Table S5.
Reassuringly, all of the 44 common barcodes were only ranked as
common in either the bone or the mouse from which they were derived
(consistent with what was seen in the first in vivo experiment). There were
35 different sequences within these 44 common barcodes, with 7 of these
barcodes belonging to the common subclass at more than one tumor site
within the same mouse (Supplementary Table S5). These findings are
consistent with the occasional metastasis of myeloma cells from one bone
to another, a phenomenon which we next examined in more detail.
Evidence of Metastasis
The ability to tag myeloma PCs with heritable DNA barcodes
should also allow for the assessment of the direct relationship between
individual myeloma cells present at distant sites within the same
mouse. If cells within tumors from different long bones show a
common ancestry, this would imply metastasis between different
tumor sites — a feature for which there were limited data in this
mouse model.
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by the potential for cross-contamination between samples (as was seen
when examining the single clones earlier). Some potential cross-
contamination between samples was evident with a number of
individual barcodes observed in many bones from different mice, the
most common pattern relating to a very high frequency barcode in
one sample being seen at very low frequency in several other samples
(Supplementary Table S4). When limiting the analysis to barcodes
unique to each mouse, there were still many examples of apparent
metastases among the read counts for the rare (b0.1%) subclass of
barcodes — but in these cases, it was impossible to truly differentiate
metastasis of a very high frequency barcode from an intersample
contamination error. This issue points to the limitations of the
barcoding approach to accurately enumerate metastasis. Despite these
caveats, there were clearer examples of metastases observed in this
model. Mouse 1.2 was the most apparent example which exhibited
evidence of multiple metastases, where six of the “common” (N5%)
barcodes showed evidence of being in the “common” subclass of
barcode in more than one long bone (Figure 4, Supplementary Table
S5). These barcodes showed the following differential read counts
across two to three different bones within the same mouse: (barcode
#1) 58381, 4663, and 3491; (barcode #2) 43315, 5474, and 4399;
(barcode #3) 46155 and 2354; (barcode #4) 42937 and 2548;
(barcode #5) 41333 and 3788; and (barcode #6) 33453 and 1987.
To further address the impact that the intersample contamination
could have on enumeration of the rare subclass of barcodes, we
evaluated whether each of the 1273 individual barcodes was unique to
each bone or to each mouse. Almost half (45.2%) of the rare (b0.1%)
subclass of barcode sequences was unique to each tumor or mouse
(Supplementary Table S6). Even after removing all of the “rare”
barcodes that could result from potential contamination issues, “rare”
barcodes still greatly outnumbered the “common” barcodes present in
each tumor. As such, the “rare” barcodes were usually observed at least
one order of magnitude more frequently than the common barcodes
(mean 16.4-fold ± SD 12.5). As such, these studies suggest that
typically only 1 out of every 16 cells that become a long-term bone
marrow PCwill become highly proliferative (Supplementary Table S6).
Discussion
MM is characterized by the presence of multiple clonal PC tumors
which are disseminated throughout the skeleton [1]. Myeloma can be
viewed as the archetype of a cancer that has arisen as a result of
metastases of circulating PCs to multiple distal sites from the initial
site of growth [11]. As such, an understanding of the mechanisms and
characteristics of the myeloma PC trafficking and metastasis is crucial
to understanding disease initiation, progression, and relapse following
therapy.
Using DNA barcoding of 5TGM1 PCs, prior to administration to
C57BL/KaLwRij mice, we have been able to use cell-lineage tracking
to examine the fates and net tumor contribution of individual MM
PCs in vivo. This approach revealed that only a small proportion
(approximately 0.01%) of the myeloma PCs injected migrate to, and
are retained within, the bone marrow of each long bone. A more
striking finding was that the progeny of only a small number of PCs
(always fewer than nine cells and often less than three cells)
contributed to the majority of the tumor burden in each long bone at
day 28. To this end, we estimated that for each proliferative myeloma
cell that makes a substantial contribution to tumor burden, 16 times
as many PCs remain dormant. This skewing of the growth ofindividual cells was not seen in in vitro cultures of the same duration,
suggesting that there are strong selection pressures in vivo. Similar
examples of clonal growth heterogeneity have previously been
observed using DNA barcoding in xenogeneic transplants. The
HCT-116 colorectal cancer cell line was barcoded using uninduced
shRNAs as neutral DNA tags and then grown subcutaneously in
immunodeficient mice [37]. After 12 days of growth, deep
sequencing of the xenograft revealed that only 6% of the injected
cells contributed to 95% of the total aggregate cell number, while
75% of the injected cells had undergone less than 2 cell divisions. By
contrast, DNA barcode complexity was maintained in vitro, with
95% of descendant barcoded cells being derived from 80% of the
initially tagged clones. Clonal growth heterogeneity in vivo has also
been demonstrated using other cell lines [37]. By contrast, xenografts
of a barcoded HCC827 small cell lung cancer cell line exhibit less
population skewing in vivo when compared with growth in vitro [38].
The more pronounced skewing of the growth trajectories of
individual PCs in our model may be the result of using an orthotopic
and syngeneic model, whereby a relatively small number of cells
(rather than a large bolus of cells) end up being dispersed throughout
their native bone marrow environment where they can be subjected to
differential gradients of growth-supportive/-suppressive factors. This
is consistent with a limited number of very strong and very localized
microenvironmental selection pressures within the bone marrow.
Very recent findings using xenografts of barcoded primary B-ALL
leukemic cells also showed clonal dominance in vivo [39]. To this
end, patient-derived xenografts in the bone marrow were highly
polyclonal with tens to hundreds of barcodes being detectable
following injection of 250,000 cells. Comparison of different skeletal
sites in the same recipient mouse showed that often N80% of the
barcodes per tumor site were contributed by only 3 to 7 barcodes. In
contrast, this clear clonal dominance was not seen in the bone marrow
of mice xenografted with a barcoded SupB15 leukemic cell line, but
there were still significantly fewer clones compared to the same cells
cultured in vitro [43]. Interestingly, the authors also noted a degree of
“metastasis” of their patient xenografts, with the same group of
barcodes often seen in more than one skeletal site and the relative
frequencies of each of these barcodes at each site being moderately
different [39]. Our studies showed even more marked spatial
asymmetry — where often the predominant clones/barcodes in one
bone are barely detectable above background levels in other bones.
The findings presented here are consistent with our previous
studies examining longitudinal tracking of 5TGM1 myeloma cell fate
determination using intravital imaging and dye labeling to differen-
tiate dormant from actively dividing myeloma cells [9]. Large
numbers of individual myeloma cells were shown to migrate to the
endosteal bone surfaces of femurs by day 7 post cell injection. At these
sites, the cells were held in a long-term dormant state, in part by
soluble factors produced by osteoblasts. By contrast, only a limited
number of regions of active myeloma cell growth were observed,
peaking with ~15 colonies per femur at day 14 post tumor cell
administration. At all of the time points examined, the numbers of
isolated, individual myeloma cells seen in the bone marrow were
always significantly more than the number of myeloma cell colonies.
At day 7, the number of individual cells observed at this point was
approximately 50 compared with 2 to 3 colonies of active cell growth.
These findings bear striking similarity to our DNA-barcoding
estimates from day 28, where there were 16 relatively quiescent
MM cells for each highly proliferative MM cell. Our ability to track
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the areas of focal cell growth described in Lawson et al. [9] are likely to
be clonal in origin and that at least some of the individual MM cells
observed at sites distant to these colonies are likely to be
independently migrated cells rather than cells that have been “shed”
by the growing colonies. Both these studies highlight the fact that
unrestricted cell growth and tumor formation are not the inevitable
outcome for a myeloma PC that has successfully migrated to and
become resident in the bone marrow. The bone marrow is a complex
microenvironment with distinct niches, each of which has a different
cellular composition and function, such as the well-characterized
endosteal/osteoblastic and vascular niches that support HSC
(haematopoietic stem cell) maintenance and dissemination [40–42].
Myeloma PCs have well-characterized interactions with cellular
elements of the bone marrow, including osteoclasts, osteoblasts,
stromal cells, macrophages, and endothelial cells [11,43], many of
which produce stimulatory and antiapoptotic factors. It is likely to be
the balance between prostimulatory (e.g., stromal cell–produced IL-6
[44]) and growth-inhibiting (e.g. osteoblast-produced decorin [45],
or host-derived matrix metalloproteinase-7 [46]) factors that will
determine the growth rate of a mutated PC.
MM is almost invariably preceded by the premalignant condition
of monoclonal gammopathy of undetermined significance (MGUS)
characterized by a lower mutant PC burden and lack of any end organ
damage [4]. MM can also be preceded by an intermediate
asymptomatic state known as smoldering MM (SMM) [47]. It has
been traditionally viewed that the transition from asymptomatic
MGUS/SMM to MM is associated with an increased mutational
burden in the clonal PC, resulting in increased activation of
tumorigenic pathways [5]. Indeed, the average number of NS-SNV
mutations in MGUS PCs does seem to be lower than that seen in
MM PCs [48,49]. However, examination of matched samples taken
from patients before and after malignant transformation has shown
that MGUS/SMM PCs can be genetically complex [6] and that
transition is often associated with the accumulation of very few new
mutations [49,50]. Furthermore, recent xenograft studies have shown
that MGUS PCs have similar tumorigenic potential to MM PCs [51].
These findings suggest that extrinsic factors play an important role in
malignant transformation, with disease progression being triggered
by cues from the microenvironment [43]. For instance, MGUS
patients with increased bone resorption have been seen to be
more likely to develop overt myeloma [52], and induction of
bone resorption can increase tumor growth in a mouse model of
myeloma [53].
Using DNA barcoding to track myeloma PC fate has proved to
have its own technical challenges. The problem of closely related
barcodes “piggy backing” as sequence errors when particular barcodes
become very abundant has previously been raised as a potential
concern with this technology [54]. We would recommend that
barcodes with up to two mismatches or in\dels from these abundant
barcodes be excluded from further analysis. Despite the inclusion of
technical replicates, intersample contaminants that required exclusion
were also evident. The modest frequency of double viral-integration
events (i.e., 29% of 5TGM1 cells tagged with two barcodes) evident
from the sequence analysis of single sorted cells (data not shown) also
means that we cannot definitively discount the possibility that, in
some individual long bones, we may have overestimated the number
of “seed cells” whose progeny went on to contribute to the tumors at
day 28. With these recommendations in mind, DNA barcodingwould be a useful tool for tracking cell fate in cancers that metastasize
to bone, particularly breast and prostate cancer [55,56]. It would also
prove interesting to examine whether stimulation of bone remodeling
(e.g., following sRANKL exposure) would alter the proportions of
frequent and rare barcodes in our model system, as osteoclast
activation has previously been associated with a release of MM cells
from dormancy [9].
Conclusion
We have used heritable DNA tags or barcodes to label a clonal
population of myeloma cells and enumerate the numbers of cells
which become long-term resident in the bone marrow in vivo. The
myeloma cells displayed striking differences in their growth
trajectories, with the progeny of less than nine myeloma cells (often
less than three cells) contributing to the bulk of the tumor in each
long bone by disease end point. Such skewed growth was not
observed in vitro and highlights the strong selection pressures to
which myeloma cells are subjected to in the bone marrow
microenvironment. We have termed this phenomenon “habitual
clonal dominance,” and it is consistent with the previous studies
demonstrating that the majority of myeloma cells are relatively
quiescent. Multiple myeloma is almost invariably preceded by an
asymptomatic condition with a lower tumor cell burden, and our
results suggest that extrinsic (bone marrow–derived) factors could
play an important part in expanding PC numbers and triggering
transition from asymptomatic to diagnostic MM. Our findings also
suggest that targeting such niche components, be they activators of
proliferation or quiescence of myeloma cells, will be an increasingly
important therapeutic strategy.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2017.09.004.
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